179 related articles for article (PubMed ID: 24659946)
1. Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?
Ziemann M; Hennig H
Transfus Med Hemother; 2014 Feb; 41(1):40-4. PubMed ID: 24659946
[TBL] [Abstract][Full Text] [Related]
2. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.
Ziemann M; Juhl D; Görg S; Hennig H
Transfusion; 2013 Oct; 53(10):2183-9. PubMed ID: 23581526
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.
Ziemann M; Krueger S; Maier AB; Unmack A; Goerg S; Hennig H
Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525
[TBL] [Abstract][Full Text] [Related]
4. Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions.
Josephson CD; Castillejo MI; Caliendo AM; Waller EK; Zimring J; Easley KA; Kutner M; Hillyer CD; Roback JD
Transfus Med Rev; 2011 Apr; 25(2):125-32. PubMed ID: 21345642
[TBL] [Abstract][Full Text] [Related]
5. Transfusion-transmitted CMV infection - current knowledge and future perspectives.
Ziemann M; Thiele T
Transfus Med; 2017 Aug; 27(4):238-248. PubMed ID: 28643867
[TBL] [Abstract][Full Text] [Related]
6. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections.
Ziemann M; Heuft HG; Frank K; Kraas S; Görg S; Hennig H
Transfusion; 2013 May; 53(5):1088-94. PubMed ID: 23320406
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
Nichols WG; Price TH; Gooley T; Corey L; Boeckh M
Blood; 2003 May; 101(10):4195-200. PubMed ID: 12531791
[TBL] [Abstract][Full Text] [Related]
8. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
[TBL] [Abstract][Full Text] [Related]
9. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
[TBL] [Abstract][Full Text] [Related]
10. Survey of Institutional Policies for Provision of "CMV-Safe" Blood in Ontario.
Finlay L; Nippak P; Tiessen J; Isaac W; Callum J; Cserti-Gazdewich C
Am J Clin Pathol; 2016 Nov; 146(5):578-584. PubMed ID: 28430958
[TBL] [Abstract][Full Text] [Related]
11. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
[TBL] [Abstract][Full Text] [Related]
12. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
13. Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation.
Shigemura T; Yanagisawa R; Komori K; Morita D; Kurata T; Tanaka M; Sakashita K; Nakazawa Y
Transfusion; 2019 Oct; 59(10):3065-3070. PubMed ID: 31322734
[TBL] [Abstract][Full Text] [Related]
14. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
Wu Y; Zou S; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Wang JH; Champion M; Fang C; Dodd R
Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585
[TBL] [Abstract][Full Text] [Related]
15. Prevention of transfusion-transmitted cytomegalovirus infection.
Pamphilon DH; Rider JR; Barbara JA; Williamson LM
Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
[TBL] [Abstract][Full Text] [Related]
16. Transfusion-associated cytomegalovirus infections.
Adler SP
Rev Infect Dis; 1983; 5(6):977-93. PubMed ID: 6318291
[TBL] [Abstract][Full Text] [Related]
17. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of Cytomegalovirus among Voluntary Blood Donors.
Chaudhari CN; Bindra MS
Med J Armed Forces India; 2009 Jul; 65(3):252-4. PubMed ID: 27408259
[TBL] [Abstract][Full Text] [Related]
19. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
[TBL] [Abstract][Full Text] [Related]
20. Infectivity of blood products containing cytomegalovirus DNA: results of a lookback study in nonimmunocompromised patients.
Ziemann M; Juhl D; Brockmann C; Görg S; Hennig H
Transfusion; 2017 Jul; 57(7):1691-1698. PubMed ID: 28370032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
